Cell-free DNA from clinical testing as a resource of population genetic analysis

Trends Genet. 2024 Nov 22:S0168-9525(24)00258-0. doi: 10.1016/j.tig.2024.10.007. Online ahead of print.

Abstract

As a noninvasive biomarker, cell-free DNA (cfDNA) has achieved remarkable success in clinical applications. Notably, cfDNA is essentially DNA, and conducting whole-genome sequencing (WGS) can yield a wealth of genetic information. These invaluable data should not be confined to one-time use; instead, they should be leveraged for more comprehensive population genetic analysis, including genetic variation spectrum, population structure and genetic selection, and genome-wide association studies (GWASs), among others. Such research findings can, in turn, facilitate clinical practice, enabling more advanced and accurate disease predictions. This review explores the advantages, challenges, and current research areas of cfDNA in population genetics. We hope that this review can serve as a new chapter in the repurposing of cfDNA sequence data generated from clinical testing in population genetics.

Keywords: cell-free DNA; clinical testing; complex traits and diseases; genome-wide association study; population genetics; whole-genome sequencing.

Publication types

  • Review